Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111-DOTA-h11B6

A radioimmunoconjugate containing the recombinant immunoglobulin G1 (IgG1) kappa humanized monoclonal antibody h11B6 that targets human kallikrein-2 (HK2) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope indium In 111, with potential use as an imaging agent. Upon administration of indium In 111-DOTA-h11B6, the h11B6 moiety targets and binds to HK2. Upon binding and radioimaging, HK2-expressing tumor cells can be visualized and the binding of h11B6 can be assessed. HK2 is overexpressed on a variety of cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	111In-DOTA-h11B6 indium-111 radiolabeled h11B6

indium In 111-DOTA-h11B6

Search NCI's Drug Dictionary